Information about Brentuximab
Liver safety of Brentuximab
Brentuximab vedotin has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.
Mechanism of action of Brentuximab
Brentuximab (bren tux’ i mab) vedotin (ve doe’ tin) is a chimeric mouse-human monoclonal IgG1 antibody to the human CD30 cell surface marker, which is also known as tumor necrosis factor receptor superfamily, member 8 and which is expressed on malignant cells particularly in Hodgkin lymphoma. The monoclonal antibody is conjugated to a microtubule inhibitor, monomethyl auristatin E (MMAE, also known as vedotin). When brentuximab vedotin binds to CD30, it is inteRNAlized and the MMAE is released by the action of lysosomal enzymes on the linker molecule that joins brentuximab to vedotin. This monoclonal antibody conjugate has been shown to be effective in inducing remissions in refractory Hodgkin lymphoma and anaplastic large cell lymphoma, and was approved for these indications in the United States in 2011.
Dosage and administration for Brentuximab
Brentuximab is available as a lyophilized powder (50 mg) and in liquid solution in (50 mg in 25 mL) in single dose vials under the brand name Adcetris. The recommended regimen is 1.8 mg/kg by intravenous infusion every three weeks until disease progression or unacceptable toxicity.
Side effects of Brentuximab
Common side effects include infusion reactions, peripheral neuropathy, fatigue, nausea, diarrhea, headache, skin rash, chills, fever, leucopenia and thrombocytopenia. Less common, but serious side effects include infections, severe cutaneous reactions including Stevens Johnson syndrome, tumor lysis syndrome, peripheral neuropathy, pulmonary toxicity and progressive multifocal leukoencephalopathy.
Cost and Coupons - Brentuximab
- GoodRx compare cost & coupons for Brentuximab
- Find the lowest cost of Brentuximab
- Search for Coupons for Brentuximab
Reviews for Brentuximab